Uri Yablonka - Brainstorm Cell COO and Director

BCLI Stock  USD 1.73  0.07  3.89%   

Director

Mr. Uri Yablonka is Executive Vice President, Chief Business Officer, Director of the Company. Prior to joining the Company, Mr. Yablonka served since December 2010 as owner and General Manager of Uri Yablonka Ltd., a business consulting firm. He also served since January 2011 as Vice President, Business Development at ACC International Holdings Ltd. . Holdings is also an affiliate of ACCBT Corporationration Prior to serving with Holdings, Mr. Yablonka served as Senior Partner of PMPR Media Consulting Ltd. From 2008 to January 2011, Mr. Yablonka was Senior Partner at PMPR Media Consulting Ltd., where he led public relations and strategy consulting for a wide range of governmental and private organizations. From 2002 to 2008, he served as a correspondent at the Maariv Daily News Paper, including extensive service as a Diplomatic Correspondent. We believe that Mr. Yablonkas skills and experience provide the variety and depth of knowledge, judgment and vision necessary for the effective oversight of the Company. His experience in business consulting and development and media experience are expected to be valuable to the Company in its current stage of growth and beyond, and his governmental experience can provide valuable insight into issues faced by companies in regulated industries such as ours. since 2017.
Age 48
Tenure 8 years
Address 1325 Avenue of Americas, New York, NY, United States, 10019
Phone201 488 0460
Webhttps://www.brainstorm-cell.com

Uri Yablonka Latest Insider Activity

Tracking and analyzing the buying and selling activities of Uri Yablonka against Brainstorm Cell stock is an integral part of due diligence when investing in Brainstorm Cell. Uri Yablonka insider activity provides valuable insight into whether Brainstorm Cell is net buyers or sellers over its current business cycle. Note, Brainstorm Cell insiders must abide by specific rules, including filing SEC forms every time they buy or sell Brainstorm Cell'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Brainstorm Cell Management Efficiency

The company has return on total asset (ROA) of (2.1584) % which means that it has lost $2.1584 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.219) %, meaning that it created substantial loss on money invested by shareholders. Brainstorm Cell's management efficiency ratios could be used to measure how well Brainstorm Cell manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Brainstorm Cell's Return On Capital Employed is increasing as compared to previous years. The Brainstorm Cell's current Return On Equity is estimated to increase to 3.34, while Return On Tangible Assets are projected to decrease to (3.86). As of now, Brainstorm Cell's Total Assets are increasing as compared to previous years. The Brainstorm Cell's current Other Current Assets is estimated to increase to about 661.7 K, while Non Current Assets Total are projected to decrease to under 1.6 M.
Brainstorm Cell Therapeutics currently holds 672 K in liabilities with Debt to Equity (D/E) ratio of 0.6, which is about average as compared to similar companies. Brainstorm Cell Ther has a current ratio of 1.6, which is within standard range for the sector. Note, when we think about Brainstorm Cell's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 3 records

DIRECTOR Age

Zheng WeiConnect Biopharma Holdings
60
James CassellaTrevi Therapeutics
70
Raquel MSHCW Biologics
N/A
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. Brainstorm Cell operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 43 people. Brainstorm Cell Therapeutics (BCLI) is traded on NASDAQ Exchange in USA. It is located in 1325 Avenue of Americas, New York, NY, United States, 10019 and employs 29 people. Brainstorm Cell is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Brainstorm Cell Ther Leadership Team

Elected by the shareholders, the Brainstorm Cell's board of directors comprises two types of representatives: Brainstorm Cell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Brainstorm. The board's role is to monitor Brainstorm Cell's management team and ensure that shareholders' interests are well served. Brainstorm Cell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Brainstorm Cell's outside directors are responsible for providing unbiased perspectives on the board's policies.
Antal PearlLendner, VP Counsel
Daniel Offen, Chief Advisor
Ibrahim MD, Executive Officer
Mary Turner, Senior Affairs
Hartoun Hartounian, Executive COO
Netta BlondheimShraga, Senior Development
Stacy Lindborg, CoChief Officer
Ralph Kern, COO and Chief Medical Officer
Chaim Lebovits, President CoCEO
PharmD MBA, Ex COO
Yael Gothelf, Vice Affairs
Irit DSc, CoFounder Board
William White, Senior Pricing
Uri Yablonka, COO and Director

Brainstorm Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Brainstorm Cell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Brainstorm Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brainstorm Cell. If investors know Brainstorm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brainstorm Cell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.45)
Return On Assets
(2.16)
Return On Equity
(11.22)
The market value of Brainstorm Cell Ther is measured differently than its book value, which is the value of Brainstorm that is recorded on the company's balance sheet. Investors also form their own opinion of Brainstorm Cell's value that differs from its market value or its book value, called intrinsic value, which is Brainstorm Cell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brainstorm Cell's market value can be influenced by many factors that don't directly affect Brainstorm Cell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brainstorm Cell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Brainstorm Cell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brainstorm Cell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.